Table 5 Application of LPHNPs for drug delivery to liver cancer
Sr. No | Lipid component | Polymer Component | Targeting moiety | Drug | In vitro | In vivo | Ref |
|---|---|---|---|---|---|---|---|
1 | Phospholipids and DSPE-PEG-2000 | PLGA | _ | Psoralen | HepG2/ADR | _ | [268] |
2 | DSPE-PEG-Malemide | PLGA | EGFR antibodies | Adriamycin | SMMC-721 | _ | [269] |
3 | Soya lecithin, DOTAP | Hyaluronic acid | Hyaluronic acid | Sorafenib | HepG2 | Kunming mice | [270] |
4 | DSPE-PEG-Malemide, Egg lecithin | PLGA | iRGD | DOX and Sorafenib | HepG2 | Rat model | [271] |